Display Single Record

FOI Request

Disclosure ID
FOI/03340
Request Date
September 27, 2019
Subject
Risankizumab
Description

Recently NICE approved the use of risankizumab (Skyrizi) for treating moderate to severe plaque psoriasis in adults.

Has your trust any patients on this treatment ? If yes, how many?

Response

We can confirm our Trust has not started any patients on this treatment yet.

Attachment 1
Attachment 2
Attachment 3
Attachment 4
Attachment 5
Attachment 6
Attachment 7
Attachment 8
Attachment 9